Upgrade to SI Premium - Free Trial

Biogen (BIIB) PT Raised to $430 at Stifel

October 23, 2017 11:53 AM
Stifel analyst Thomas Shrader raised his price target on Biogen (NASDAQ: BIIB) to $430.00 (from $415.00) while maintaining a Buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles